Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the pandemic. "We're going to make a significant impact on this Covid pandemic," CEO Stanley Erck told...
finance.yahoo.com